Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announces that it has entered into a definitive agreement to be acquired by affiliates of Altaris, LLC (“Altaris”), an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, in an all-cash transaction. At or about the closing of the transaction, Altaris anticipates the Company will be combined with Chemical Computing Group (“CCG”), an existing Altaris portfolio company.
Read the full article: Simulations Plus to Be Acquired by Altaris for Approximately $375M //
Source: https://www.businesswire.com/news/home/20260616126655/en/Simulations-Plus-to-Be-Acquired-by-Altaris-For-Approximately-%24375-Million